ReviewTrends in pharmacological sciences2019
Pharmacogenomic Approach to Antimyopia Drug Development: Pathways Lead the Way.
Review in Trends in pharmacological sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 37 citations in OpenAlex.
- Acute Effects of Oral Caffeine Intake on Human Global-Flash mfERG Responses: A Placebo-Controlled, Double-Masked, Balanced Crossover Study.Investigative ophthalmology & visual science · 2024Trial
- Comparison of Changes in Retinal Vascular Density and Thickness After Using Low-Level Red Light and 0.01% Atropine in Premyopic Children.Translational vision science & technology · 2024Trial
- Inhibition of Retinal AdoRA2a Activity Attenuates Myopia Progression.Investigative ophthalmology & visual science · 2026Article
- Atropine-Loaded Contact Lens Sustained-Release Systems: A Narrative Review for the New Frontier for Myopia Management.Ophthalmology and therapy · 2026Review
- Navigating the Core Challenges of Atropine Therapy in Myopia: A Mechanistic and Clinical Analysis of Dose, Response, and Durability.Journal of ophthalmology · 2026Review
- Article
- Progress in Methylxanthine Biosynthesis: Insights into Pathways and Engineering Strategies.International journal of molecular sciences · 2025Review
- Identification of Potential Drug Targets for Myopia Through Mendelian Randomization.Investigative ophthalmology & visual science · 2024Article
- Article
- Applications of Genomics and Transcriptomics in Precision Medicine for Myopia Control or Prevention.Biomolecules · 2023Review
- Ocular Perfusion Pressure in 7- and 12-Year-Old Chinese Children: The Anyang Childhood Eye Study.Translational vision science & technology · 2022Article
- Rare ocular toxicity induced by pertuzumab/QL1209 in healthy chinese subjects: case reports and whole-exome sequencing analysis.Investigational new drugs · 2022Article
- Short-Term Effects of Atropine 0.01% on the Structure and Vasculature of the Choroid and Retina in Myopic Chinese Children.Ophthalmology and therapy · 2022Article
- Dietary ω-3 polyunsaturated fatty acids are protective for myopia.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Functional integration of eye tissues and refractive eye development: Mechanisms and pathways.Experimental eye research · 2021Review
- Genome-wide analysis of retinal transcriptome reveals common genetic network underlying perception of contrast and optical defocus detection.BMC medical genomics · 2021Article
- Update and guidance on management of myopia. European Society of Ophthalmology in cooperation with International Myopia Institute.European journal of ophthalmology · 2021Article
- IMI 2021 Yearly Digest.Investigative ophthalmology & visual science · 2021Review
- The Changes of KCNQ5 Expression and Potassium Microenvironment in the Retina of Myopic Guinea Pigs.Frontiers in physiology · 2021Article
- Increased Choroidal Blood Perfusion Can Inhibit Form Deprivation Myopia in Guinea Pigs.Investigative ophthalmology & visual science · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Myopia is the most common eye disorder in the world which is caused by a mismatch between the optical power of the eye and its excessively long axial length. Recent studies revealed that the regulation of the axial length of the eye occurs via a complex signaling cascade, which originates in the retina and propagates across all ocular tissues to the sclera. The complexity of this regulatory cascade has made it particularly difficult to develop effective antimyopia drugs. The current pharmacological treatment options for myopia are limited to atropine and 7-methylxanthine, which have either significant adverse effects or low efficacy. In this review, we focus on the recent advances in genome-wide studies of the signaling pathways underlying myopia development and discuss the potential of systems genetics and pharmacogenomic approaches for the development of antimyopia drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.